Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection

References

• Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793.
   PubMed Web of Science ®Google Scholar
• Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet. 2020;396:514–515.
   Web of Science ®Google Scholar
• To KKW, Cheng VCC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microb. 2020;1:E111–E118.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden R, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2035389
   Web of Science ®Google Scholar
• Voysey M C, Madhi SA SAC, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020. DOI:https://doi.org/10.1016/S0140-6736(20)32661-1
   Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020. DOI:https://doi.org/10.1016/S1473-3099(20)30843-4
   Google Scholar
• Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
   PubMed Web of Science ®Google Scholar
• Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406–1407.
   PubMed Web of Science ®Google Scholar
• Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon β-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704.
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323:1824–1836.
   PubMed Web of Science ®Google Scholar
• Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778–809.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221–18.
   PubMed Web of Science ®Google Scholar
• Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020;32:107940.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 – final report. N Engl J Med. 2020;383:1813–1826.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
   PubMed Web of Science ®Google Scholar
• Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. Br Med J. 2020. DOI:https://doi.org/10.1136/bmj.m2924
   Google Scholar
• Vandewalle J, Luypaert A, De Bosscher K. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018;29:42–54.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2021436
   Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–1316.
   PubMed Web of Science ®Google Scholar
• Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa1177
   Google Scholar
• Li Y, Zhou X, Li T, et al. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. Emerg Microbes Infect. 2020;9:1869–1877.
   PubMed Web of Science ®Google Scholar
• Fung SY, Yuen KS, Ye ZW, et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9:558–570.
   PubMed Web of Science ®Google Scholar
• Gallily R, Warwick A, Bang FB. Effect of cortisone of genetic resistance to mouse hepatitis virus in vivo and in vitro. Proc Natl Acad Sci USA. 1964;51:1158–1164.
   Web of Science ®Google Scholar
• Datta DV, Isselbacher KJ. Effects of corticosteroids on mouse hepatitis virus infection. Gut. 1969;10:522–529.
   Web of Science ®Google Scholar
• Auyeung TW, Lee JSW, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51:98–102.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Al-Hameed F. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–767.
   PubMed Web of Science ®Google Scholar
• Wang PH, Ye ZW, Deng JJ, et al. Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16. EMBO Rep. 2018;19:e45737.
   Web of Science ®Google Scholar
• Chan JFW, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71:2428–2446.
   PubMed Web of Science ®Google Scholar
• Chan JFW, Yuan S, Zhang AJ, et al. Surgical mask partition reduces the risk of non-contact transmission in a golden Syrian hamster model for coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;71:2139–2149.
   PubMed Web of Science ®Google Scholar
• To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574.
   PubMed Web of Science ®Google Scholar
• Chan JFW, Yip CCY, To KKW, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol. 2020;58:e00310–20.
   PubMed Web of Science ®Google Scholar
• Yang D, Chu H, Hou Y, et al. Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020;222:734–745.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Nasir JA, Budylowski P, et al. Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26:2054–2063.
   PubMed Web of Science ®Google Scholar
• Sia SF, Yen LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583:834–838.
   PubMed Web of Science ®Google Scholar
• Liu J, Zheng X, Huang Y, et al. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol. 2020;146:325–327.
   PubMed Web of Science ®Google Scholar
• Ohishi W, Chayama K. Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy. Clin Exp Nephrol. 2011;15:634–640.
   Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975.
   PubMed Web of Science ®Google Scholar
• Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microb. 2020;28:117–123.
   PubMed Web of Science ®Google Scholar
• Huo J, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27:846–854.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xu W, Xia S, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020;5:282.
   PubMed Web of Science ®Google Scholar
• Reynolds CJ, Swadling L, Gibbons JM, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020;5:eabf3698.
   Web of Science ®Google Scholar
• Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180:1356–1362.
   PubMed Web of Science ®Google Scholar
• Choe PG, Kang CK, Suh HJ, et al. Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection. Emerg Infect Dis. 2021;27:327–329.
   Web of Science ®Google Scholar
• Mangalmurti N, Hunter CA. Cytokine storms: Understanding COVID-19. Immunity. 2020;53:19–25.
   PubMed Web of Science ®Google Scholar
• Strehl C, Ehlers L, Gaber T, et al. Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 2019;10:1744.
   Web of Science ®Google Scholar